Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT07424547
This study is recruiting at 5 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer
- Solid Tumor Cancer
- Advanced Metastatic Cancer
- Prostate
- Small Cell Lung Cancer
- Ovarian Cancer
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Last updated on ClinicalTrials.gov
- April 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- BRCR Global · Plantation, FL
- Florida Clinical Trials Group · Plantation, FL
Texas · 2
- NEXT Oncology Austin · Austin, TX
- NEXT Oncology San Antonio · San Antonio, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.